Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Hikma Pharmaceutical (HIK)

  Print      Mail a friend       Annual reports

Friday 19 August, 2011

Hikma Pharmaceutical

Trading Statement

RNS Number : 7130M
Hikma Pharmaceuticals Plc
19 August 2011




Trading update                                                                     


London, 19 August, 2011:  Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) ("Hikma"), the global pharmaceutical group, is today providing the following update on trading.

Since the beginning of the year, the overall performance of the Group has been good and the Group remains on track to deliver around 7% organic revenue growth for the full year, with a gross margin of around 47%. 

In the Branded business, our team in the MENA region has done an excellent job managing unprecedented disruptions in certain markets and has strengthened our sales and manufacturing operations.  We are on track to deliver our forecast for the first half, in line with market expectations, driven by a recovery in Egypt and Tunisia and double-digit growth in most other markets.  While sales activities in Libya and Yemen remain limited and in certain markets ACTOS® sales have been suspended or negatively impacted by more restrictive labeling, we continue to expect the Branded business to deliver around 7% revenue growth for the full year, with operating margins of around 23%.

In the US, our team has gone a long way towards off-setting lost sales from the discontinuation of colchicine and we continue to expect Generics revenues of around $160 million for the full year.  Given investments we have made to strengthen the senior management team, we expect operating margin for the full year to be in the low-teens.

Our legacy Injectables business is having an excellent year and is delivering on our strategy of building scale through strong organic growth.  We expect this strong performance to continue in the second half and expect significant operating margin expansion for the full year.  

Due to the significant delay in the closing the MSI transaction, caused by an extended FTC review, we incurred higher than expected integration and transaction costs of $5.4 million, which have resulted in a net loss from MSI of around $5.0 million for the two months to 30 June, taking into consideration financing costs. Since closing on 2 May 2011, the integration process has proceeded apace.  We have identified opportunities for cost savings, operational synergies and portfolio optimization and are well advanced in the implementation of our restructuring plans.  We expect the MSI business will break even for the second half of the year.  For 2012, we expect MSI to contribute revenues of at least $180 million and EBITDA margin of at least 10%.

Negative movements in the Sudanese Pound, the Egyptian Pound, the Japanese Yen and the Euro relative to the dollar are also having a material impact on our results.  We now expect reported net income for the Group to be in the range of $85 million to $90 million for the full year, including one-time transaction and integration costs and assuming current exchange rates.  In constant currency, however, we expect Group net income to be in the range of $95 million to $100 million, including one-time transaction and integration costs.

We will announce our interim results for the six months to 30 June on 25 August 2011.

-----  ENDS -----



Hikma Pharmaceuticals PLC

Susan Ringdal, Investor Relations Director                          +44 (0)20 7399 2760/07776 477 050


Financial Dynamics                                                                         +44 (0)20 7831 3113

Ben Atwell /Julia Phillips/Jonathan Birt/Matthew Cole


About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2010, Hikma achieved revenues of $731 million and profit attributable to shareholders of $99 million. 



This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t